Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients

This study is testing a new treatment called NRG-103, injected directly into a tumor cavity in the brain, for people with a type of aggressive brain cancer called glioblastoma (GBM) that has come back after initial treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with glioblastoma that has recurred after prior treatment - Your recurrent tumor has been surgically removed and a small reservoir device (Ommaya) has been placed in the cavity - You are in reasonably good health (Karnofsky score of 70 or above) with adequate blood, heart, liver, and kidney function **You may NOT be eligible if...** - You have had prior cell therapy, gene therapy, or oncolytic virus therapy - You have another active cancer - You have autoimmune disease, immune deficiency, or organ transplant history - You have active hepatitis B, hepatitis C, or poorly controlled diabetes - You have multiple GBM lesions or your tumor is in the brainstem or cerebellum - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.